BIOLOGICAL IMPLANT USHERS IN NEXT GENERATION SHOULDER SURGERY
Macquarie University Hospital Orthopaedic Surgeons Perform a ‘Disruptive Innovation’ procedure in first Australian Cases of Biological Implantation.
Three patients with high-grade bursal rotator cuff injury have each had a unique operation that ushers in a new generation of biological orthopaedic surgery.
The arthroscopic procedure involves a small collagen patch – the REGENETEN™. Bioinductive Implant – being placed on the rotator cuff tear and secured in place.
Over six to twelve months, the patch stimulates the body’s natural healing response to support new tendon growth. Within a year, the patch gradually absorbs, leaving a layer of tendon-like tissue and thereby slowing disease progression.
Professor Des Bokor, orthopaedic surgeon at Macquarie University Hospital who performed the procedures, says that the implant is a ‘disruptive innovation’ in orthopaedic surgery.
“All current implants are static material that stay in the body as a support,”Professor Bokor said.
“The REGENETEN Bioinductive Implant is not structural. Rather, it gradually induces the formation of new tendinous tissue over the surface of the tendon, resulting in a thicker tendon.
“The implant essentially lays down the pathway for new tissue to grow, thereby slowing or halting progression of the disease.”
Rotator cuff tears are the most common form of shoulder pain and disability, yet have been traditionally hard to heal, with small tears inevitably becoming larger.
With the body putting its energy into fighting the stress of a tear, it is unable to heal the tear itself.
The REGENETEN Bioinductive Implant works to remove that stress by creating an environment in which the body can focus on new tendon growth.
Professor Bokor first worked on developing the procedure six years ago with US-based company Rotation Medical, who developed the original concept.
Working at Macquarie University Hospital, Professor Bokor and fellow surgeons developed the instrumentation and surgical approach.
Since clearing FDA approval, more than 20,000 implants have now been done in the US. The procedure is awaiting TGA approval in Australia, with Macquarie University Hospital the only facility having been granted a licence to perform special access cases.
The procedure should be widely available in about a year. Recovery time is fast with patients resuming normal activity at six to eight weeks.
Using US data, Professor Bokor has published five year results from the procedure. He will present the findings in New Orleans in October this year and in London next June.
FOR MORE INFORMATION
Professor Des Bokor – (02) 9812 3555